Bristol-Myers Squibb Company
345 Park Avenue
About Bristol-Myers Squibb Company
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
Founder: Edward Robinson Squibb
CEO: Giovanni Caforio, MD
CFO: Charles Bancroft
Please click here for clinical trial information.
Please click here for Bristol-Myers Squibb job opportunities.
Please click here to see all products.
For more information, visit
www.bms.com and follow us on www.twitter.com/BMSNEWS.
FOLLOW BRISTOL-MYERS SQUIBB:
Tweets by Bristol-Myers Squibb
1838 articles with Bristol-Myers Squibb Company
Roche announced that its Phase III IMpower 133 clinical trial of Tecentriq (atezolizumab) plus carboplatin and etoposide chemotherapy met its co-primary endpoints.
U.S. Food and Drug Administration (FDA) Accepts Application for Opdivo Plus Low-Dose Yervoy for T...
6/21/2018Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for the treatment of first-line advanced non-small cell lung cancer...
China National Drug Administration Approves Country’s First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC)
The first and only PD-1 inhibitor approved in China opens a new era of Immuno-Oncology treatment for a type of lung cancer
Spotlight on Biopharma Fellowships: AbbVie and Keck Graduate Institute Launch PharmD Fellowship P...
6/14/2018AbbVie and the Keck Graduate Institute (KGI) School of Pharmacy have partnered to form the first AbbVie-KGI Biopharmaceutical Industry Fellowship.
Cell Medica today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Company’s Board of Directors.
Bristol-Myers Squibb to Present New Research Findings on the Treatment of Patients with Early Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)
Bristol-Myers Squibb Company today confirmed that 31 abstracts demonstrating The Company’s immunoscience-research focus may impact diverse patient subgroups will be presented at the EULAR 2018.
Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor
BIOASIS TECHNOLOGIES INC. today announced the addition of Mario Saltarelli, M.D., Ph.D., Jack Hoppin, Ph.D. and Sue O’Connor, B.Sc. (Hons), Ph.D. to its scientific advisory board.
Bristol-Myers Squibb Company will take part in Goldman Sachs 39th Annual Global Healthcare Conference.
During a conference call at 10:30 a.m. EDT on July 26, company executives will review financial information and will address inquiries from investors and analysts.
Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors
Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.
Biogen signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.
Opdivo Plus Chemotherapy Showed Improved Progression-Free Survival Versus Chemotherapy in First-Line Lung Cancer Patients with PD-L1 <1%, in CheckMate -227 Study to Be Presented at ASCO 2018
Bristol-Myers Squibb Company announced results from a part of the Phase 3 CheckMate -227 trial that evaluated Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) and Opdivo plus chemotherapy versus chemotherapy in patients with first-line advanced non-small cell lung cancer (NSCLC) with PD-L1 expression <1%, across squamous and non-squamous tumor histologies (Part 1b).
Opdivo (nivolumab) 3 mg/kg Demonstrates Sustained, Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) 10 mg/kg for Broad Range of Patients with Resected Stage III or IV Melanoma
June 4, 2018 13:00 UTC Opdivo (nivolumab) 3 mg/kg Demonstrates Sustained, Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) 10 mg/kg for Broad Range of Patients with Resected Stage III or IV Melanoma Opdivo is the only I-O therapy to demonstrate superiority versus an active control in this patient population Updated results represent longest follow-up of any PD-1 inhibitor in the adjuvant melanoma se
Bad news for Roche Holding AG. Two of its cancer drugs, Tecentriq and taselisib, have been shown to provide only modest protection from disease progression.
The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.
With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.
U.S. Food and Drug Administration Lifts Partial Clinical Hold on Opdivo (nivolumab)-based Combination Study in Multiple Myeloma
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) lifted a partial clinical hold placed on CA209-602 (CheckMate -602).
Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma in CheckMate -214 Study
Opdivo plus low-dose Yervoy is the first and only FDA-approved Immuno-Oncology combination therapy for this patient population.
Halozyme Therapeutics, Inc. will present data evaluating certain biomarkers as potential predictors of survival in patients with previously untreated metastatic pancreatic ductal adenocarcinoma at the American Society of Clinical Oncology annual meeting.
Madrigal Pharmaceuticals announced positive topline data from its Phase II clinical trial of MGL-3196 in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).